{"id":"low-dose-lamotrigine","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Rash (including Stevens-Johnson syndrome risk at higher doses)"},{"rate":"10-15","effect":"Dizziness"},{"rate":"5-10","effect":"Ataxia"},{"rate":"5-10","effect":"Diplopia"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Tremor"}]},"_chembl":{"chemblId":"CHEMBL741","moleculeType":"Small molecule","molecularWeight":"256.10"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lamotrigine stabilizes neuronal membranes primarily through sodium channel blockade, which prevents repetitive neuronal firing. At low doses, it also modulates glutamatergic neurotransmission by inhibiting the release of glutamate, an excitatory neurotransmitter. This dual mechanism makes it useful in conditions characterized by neuronal hyperexcitability or mood dysregulation.","oneSentence":"Low-dose lamotrigine reduces neuronal excitability by blocking voltage-gated sodium channels and inhibiting glutamate release.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:53:17.171Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy (adjunctive therapy)"},{"name":"Bipolar disorder (maintenance treatment, particularly bipolar depression)"},{"name":"Off-label use in mood disorders and neuropathic pain"}]},"trialDetails":[{"nctId":"NCT04274179","phase":"PHASE3","title":"Ketogenic Diet for New-Onset Absence Epilepsy","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2020-08-10","conditions":"Absence Epilepsy, Ketogenic Dieting, Epilepsy, Absence","enrollment":40},{"nctId":"NCT03689114","phase":"PHASE4","title":"Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-05-10","conditions":"Epilepsies, Partial","enrollment":58},{"nctId":"NCT06488586","phase":"","title":"IV Ketamine Vs. in Esketamine for MDD TRD","status":"RECRUITING","sponsor":"Gustavo Vazquez","startDate":"2023-03-20","conditions":"Treatment Resistant Depression","enrollment":80},{"nctId":"NCT00807989","phase":"PHASE4","title":"The Efficacy and Safety of Low Dose Combination of LTG and VPA Compared to CBZ Monotherapy","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2008-03","conditions":"Epilepsy","enrollment":207}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Low lamotrigine"],"phase":"marketed","status":"active","brandName":"Low dose lamotrigine","genericName":"Low dose lamotrigine","companyName":"Mario Negri Institute for Pharmacological Research","companyId":"mario-negri-institute-for-pharmacological-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low dose lamotrigine is used to study its efficacy and tolerability in newly diagnosed, previously untreated epilepsy. As a small molecule, lamotrigine works by blocking the sodium channel alpha subunit, which is involved in the regulation of neuronal excitability.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}